ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013
Serum antibodies to blood group A predict survival on PROSTVAC-VF.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- IgM promotes antitumor immunity to a Tn-expressing solid tumor.Journal for immunotherapy of cancer · 2026Article
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- ABO/Rh Blood Group and Cervical Cancer Survival: Results from Our Own and Other Studies.Journal of Cancer · 2024Article
- Article
- Levels of plasma glycan-binding auto-IgG biomarkers improve the accuracy of prostate cancer diagnosis.Molecular and cellular biochemistry · 2021Article
- Abnormal antibodies to self-carbohydrates in SARS-CoV-2 infected patients.bioRxiv : the preprint server for biology · 2020Article
- Glycan Reactive Natural Antibodies and Viral Immunity.Viral immunology · 2020Review
- Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy.Gynecologic oncology · 2020Article
- Anti-glycan IgM repertoires in newborn human cord blood.PloS one · 2019Article
- Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries.Frontiers in immunology · 2019Article
- Development of a Multiplex Glycan Microarray Assay and Comparative Analysis of Human Serum Anti-Glycan IgA, IgG, and IgM Repertoires.ACS omega · 2018Article
- Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins.Nature communications · 2018Article
- Article
- Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.PloS one · 2017Article
- AB0/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical Prostatectomy.Frontiers in surgery · 2017Article
- Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins.Cell chemical biology · 2016Article
- PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors.Cancer immunology research · 2016Article
- Oncolytic virotherapy for urological cancers.Nature reviews. Urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThere is evidence that therapeutic cancer vaccines can lengthen survival for some patients with cancer, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. EXPERIMENTAL
designThis retrospective study included 141 subjects from phase II trials of PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials for advanced prostate cancer. A glycan microarray was used to profile prevaccination antiglycan antibody populations in sera as potential biomarkers for PROSTVAC-VF. The screen for predictive biomarkers identified antiglycan antibodies that consistently stratified subjects into groups with different Kaplan-Meier survival estimates. Because of the potential for overfitting, a permutation test was used to estimate the false discovery rate.
resultsPrevaccination antibody levels to blood group A trisaccharide (BG-Atri) were found to have a statistically significant correlation with survival. Long-term survival was approximately doubled in subjects with abundant anti-BG-Atri immunoglobulin M (IgM) relative to subjects with little or no preexisting IgM for BG-Atri. This survival correlation was specific to vaccine treatment, as no correlation was observed in control patients immunized with wild-type poxviruses lacking the key tumor antigen, prostate-specific antigen (PSA). Moreover, anti-BG-Atri IgM levels were not correlated with general measures of disease severity, such as PSA levels, Gleason score, or Halabi predicted survival.
conclusionIn addition to reporting a new potentially predictive biomarker for PROSTVAC-VF, this study highlights the use of glycan microarray technology for improving our understanding of vaccine immunology. Clin Cancer Res; 19(5); 1290-9. ©2012 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.